Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Clinics in Laboratory MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Minimal residual disease and childhood leukemia: standard of care recommendations from the Pediatric Oncology Group of Ontario MRD Working Group.Pediatr Blood Cancer. 2016; 63: 973-982
- Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study.Blood. 2008; 111: 5477-5485
- Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study.Blood. 2010; 115: 3206-3214
- Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial.Lancet Oncol. 2013; 14: 199-209
- Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemia.Blood. 2010; 115: 4657-4663
- Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia.Blood. 2012; 120: 468-472
- Clinical significance and management of MRD in adults with acute lymphoblastic leukemia.Clin Adv Hematol Oncol. 2020; 18: 413-422
- Minimal residual disease in adult ALL: technical aspects and implications for correct clinical interpretation.Blood Adv. 2017; 1: 2456-2466
- Description and prognostic significance of the kinetics of minimal residual disease status in adults with acute lymphoblastic leukemia treated with HyperCVAD.Am J Hematol. 2018; 93: 546-552
- Use of minimal residual disease assessment to redefine induction failure in pediatric acute lymphoblastic leukemia.J Clin Oncol. 2017; 35: 660-667
- Flow-cytometric vs. -morphologic assessment of remission in childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group (COG).Leukemia. 2018; 32: 1370-1379
- Flow cytometric analysis of normal B cell differentiation: a frame of reference for the detection of minimal residual disease in precursor-B-ALL.Leukemia. 1999; 13: 419-427
- Disease detection methodologies in relapsed B-cell acute lymphoblastic leukemia: opportunities for improvement.Pediatr Blood Cancer. 2020; 67: e28149
- Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia.Leukemia. 2008; 22: 771-782
- Determination of minimal residual disease in leukaemia patients.Br J Haematol. 2003; 121: 823-838
- Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe against Cancer program.Leukemia. 2003; 17: 2318-2357
- Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia.Blood. 2012; 120: 5173-5180
- IgH-V(D)J NGS-MRD measurement pre- and early post-allotransplant defines very low- and very high-risk ALL patients.Blood. 2015; 125: 3501-3508
- Measurable residual disease detection by high-throughput sequencing improves risk stratification for pediatric B-ALL.Blood. 2018; 131: 1350-1359
- Digital droplet PCR and next-generation sequencing refine minimal residual disease monitoring in acute lymphoblastic leukemia.Leuk Lymphoma. 2019; 60: 2838-2840
- Minimal residual disease in acute lymphoblastic leukemia: technical and clinical advances.Front Oncol. 2019; 9: 726
- Time point-dependent concordance of flow cytometry and real-time quantitative polymerase chain reaction for minimal residual disease detection in childhood acute lymphoblastic leukemia.Haematologica. 2012; 97: 1582-1593
- A high-sensitivity 10-color flow cytometric minimal residual disease assay in B-lymphoblastic leukemia/lymphoma can easily achieve the sensitivity of 2-in-10(6) and is superior to standard minimal residual disease assay: a study of 622 patients.Cytometry B Clin Cytom. 2020; 98: 57-67
- Detailed immunophenotyping of B-cell precursors in regenerating bone marrow of acute lymphoblastic leukaemia patients: implications for minimal residual disease detection.Br J Haematol. 2017; 178: 257-266
- Methodological aspects of minimal residual disease assessment by flow cytometry in acute lymphoblastic leukemia: a French multicenter study.Cytometry B Clin Cytom. 2015; 88: 21-29
- Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia.Blood. 2017; 129: 347-357
- Flow-cytometric minimal residual disease monitoring in blood predicts relapse risk in pediatric B-cell precursor acute lymphoblastic leukemia in trial AIEOP-BFM-ALL 2000.Pediatr Blood Cancer. 2019; 66: e27590
- Clinical impact of minimal residual disease in children with different subtypes of acute lymphoblastic leukemia treated with Response-Adapted therapy.Leukemia. 2017; 31: 333-339
- Monitoring minimal residual disease in acute leukemia: technical challenges and interpretive complexities.Blood Rev. 2017; 31: 63-75
- B lymphoblastic leukemia minimal residual disease assessment by flow cytometric analysis.Clin Lab Med. 2017; 37: 771-785
- Marked variability in reported minimal residual disease lower level of detection of 4 hematolymphoid neoplasms: a survey of participants in the College of American Pathologists Flow Cytometry Proficiency Testing Program.Arch Pathol Lab Med. 2015; 139: 1276-1280
- A QA program for MRD testing demonstrates that systematic education can reduce discordance among experienced interpreters.Cytometry B Clin Cytom. 2018; 94: 239-249
- Participation in the College of American Pathologists Laboratory accreditation program decreases variability in B-lymphoblastic leukemia and plasma cell myeloma flow cytometric minimal residual disease testing: a follow-up survey.Arch Pathol Lab Med. 2021; 145: 336-342
- Flow cytometry of B-Cell neoplasms.Clin Lab Med. 2017; 37: 697-723
- Evaluating new markers for minimal residual disease analysis by flow cytometry in precursor B lymphoblastic leukemia.Indian J Hematol Blood Transfus. 2018; 34: 48-53
- Comparison of diagnostic and relapse flow cytometry phenotypes in childhood acute lymphoblastic leukemia: implications for residual disease detection: a report from the children's oncology group.Cytometry B Clin Cytom. 2005; 68: 18-24
- A novel flow cytometric assay for detection of residual disease in patients with B-lymphoblastic leukemia/lymphoma post anti-CD19 therapy.Cytometry B Clin Cytom. 2018; 94: 112-120
- Automated optimized parameters for T-distributed stochastic neighbor embedding improve visualization and analysis of large datasets.Nat Commun. 2019; 10: 5415
- The end of gating? An introduction to automated analysis of high dimensional cytometry data.Eur J Immunol. 2016; 46: 34-43
- Computational analysis of multiparametric flow cytometric data to dissect B cell subsets in vaccine studies.Cytometry A. 2020; 97: 259-267
- Detection of minimal residual disease in B lymphoblastic leukemia using viSNE.Cytometry B Clin Cytom. 2015; 88: 294-304
- Seventeen-colour flow cytometry: unravelling the immune system.Nat Rev Immunol. 2004; 4: 648-655
- Spectral flow cytometry-Quo vadimus?.Cytometry A. 2019; 95: 823-824
- OMIP-069: forty-color full spectrum flow cytometry panel for deep immunophenotyping of major cell subsets in human peripheral blood.Cytometry A. 2020; 97: 1044-1051
- Cellular and molecular profiling of T-cell subsets at the onset of human acute GVHD.Blood Adv. 2020; 4: 3927-3942
Article info
Footnotes
This article originally appeared in Clinics in Laboratory Medicine, Volume 41 Issue 3, September 2021.
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
